NCT06869252 Autologous Adipose Cells Therapy
| NCT ID | NCT06869252 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | CERM INC. |
| Condition | Hair Loss/Baldness |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2025-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 40 participants in total. It began in 2025-08-01 with a primary completion date of 2025-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell Therapy for skin rejuvenation and hair improvement in human application.
Eligibility Criteria
Inclusion Criteria: 1. Outpatients who express interest in skin rejuvenation, and/or who are experiencing skin conditions, such as winkles, fine lines, loss of skin elasticity, skin pigmentation, scarring. 2. Outpatients who are experiencing hair loss or hair thinning 3. Provision of signed and dated informed consent form 4. Clearly stated willingness to comply with all the procedures of the study and availability of the study 5. Female and Male aged between 21 to 80 years old 6 Medical clearance by family doctor Exclusion Criteria: 1. Pregnancy or lactation 2. Known allergic reaction to components of cell culture media 3. Chronic disease , e.g. cardiovascular disease, diabetes, chronic kidney disease, seizures 4. Chronic infections, e.g. skin fungi infection, psoriasis 5. Chronic wound healing 6. Currently taking hormone therapy 7. History of cancers and active cancers 8. Viral infection, e.g. HIV, hepatitis B, influenza, coronaviruses.
Contact & Investigator
Dr. Abdollah M. Malekzadeh, MD, MD
PRINCIPAL INVESTIGATOR
The Centre for Cosmetic Surgery & Medicine
Frequently Asked Questions
Who can join the NCT06869252 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 80 Years, studying Hair Loss/Baldness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06869252 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06869252 currently recruiting?
Yes, NCT06869252 is actively recruiting participants. Contact the research team at ankeetdixit@cermbio.com for enrollment information.
Where is the NCT06869252 trial being conducted?
This trial is being conducted at Lewes, United States, Newark, United States.
Who is sponsoring the NCT06869252 clinical trial?
NCT06869252 is sponsored by CERM INC.. The principal investigator is Dr. Abdollah M. Malekzadeh, MD, MD at The Centre for Cosmetic Surgery & Medicine. The trial plans to enroll 40 participants.